Editor's Choice Time for global action on fake and substandard drugs BMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7917 (Published 21 November 2012) Cite this as: BMJ 2012;345:e7917 Article Related content Metrics Responses Peer review Related articles Analysis How to achieve international action on falsified and substandard medicines Published: 13 November 2012; BMJ 345 doi:10.1136/bmj.e7381 Feature Faking it Published: 20 November 2012; BMJ 345 doi:10.1136/bmj.e7836 Analysis Commentary: Substandard medicines are the priority for neglected tropical diseases Published: 14 November 2012; BMJ 345 doi:10.1136/bmj.e7518 See more Cancer drugs remain FDA approved despite lack of benefit, study finds BMJ December 06, 2016, 355 i6568; DOI: https://doi.org/10.1136/bmj.i6568 Johnson & Johnson is ordered to pay $1bn over faulty hip implants BMJ December 06, 2016, 355 i6551; DOI: https://doi.org/10.1136/bmj.i6551 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Trial of novel leukaemia drug is stopped for second time after two more deaths BMJ November 25, 2016, 355 i6376; DOI: https://doi.org/10.1136/bmj.i6376 Promise of new Alzheimer’s drug is dashed after lack of evidence BMJ November 24, 2016, 355 i6362; DOI: https://doi.org/10.1136/bmj.i6362
